Trevena, Inc. (TRVN) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

3.38 k

Shareholding (Sep 2024)

FII

0.15%

Held by 6 FIIs

DII

98.51%

Held by 1 DIIs

Promoter

0.00%

How big is Trevena, Inc.?

22-Jun-2025

As of Jun 18, Trevena, Inc. has a market capitalization of 0.95 million, with net sales of 0.55 million and a net profit of -34.02 million over the latest four quarters. Shareholder's funds are at -7.66 million, and total assets are 40.60 million as of Dec 23.

What does Trevena, Inc. do?

22-Jun-2025

Trevena, Inc. is a biopharmaceutical company focused on developing therapies for pain management and migraine treatment. As of September 2024, it reported net sales of $0 million and a net loss of $5 million, with a market cap of $0.95 million.

Who are in the management team of Trevena, Inc.?

22-Jun-2025

As of March 2022, the management team of Trevena, Inc. includes Leon Moulder (Independent Chairman), Carrie Bourdow (CEO), and several independent directors: Maxine Gowen, Scott Braunstein, Michael Dougherty, Julie McHugh, and Jake Nunn. They oversee the company's strategic direction and operations.

Is Trevena, Inc. overvalued or undervalued?

20-Sep-2025

As of July 8, 2024, Trevena, Inc. is considered overvalued with negative valuation ratios and has significantly underperformed the market, with a year-to-date return of -83.33% compared to the S&P 500's 12.22%.

Is Trevena, Inc. technically bullish or bearish?

20-Sep-2025

As of September 2, 2025, Trevena, Inc. shows a mildly bearish trend due to bearish weekly MACD and KST indicators, despite some potential for recovery indicated by monthly metrics, while significantly underperforming the S&P 500 with a year-to-date return of -83.33%.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 0 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.87

Return on Equity

164.67%

Price to Book

-0.01

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Sep 2024)

Net Profit:

-5 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-95.2%

6 Months

-98.96%

1 Year

-99.28%

2 Years

-99.92%

3 Years

-99.65%

4 Years

-100.0%

5 Years

-100.0%

Trevena, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is Trevena, Inc. technically bullish or bearish?

As of 2 September 2025, the technical trend for Trevena, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, primarily driven by the weekly MACD and KST indicators, both of which are bearish. The daily moving averages also indicate a bearish trend. However, the monthly MACD and RSI show mildly bullish and bullish signals, respectively, suggesting some potential for recovery. The stock has significantly underperformed against the S&P 500, with a year-to-date return of -83.33% compared to the S&P 500's 12.22%....

Is Trevena, Inc. overvalued or undervalued?

As of 8 July 2024, Trevena, Inc. has moved from a risky to a does not qualify valuation grade. The company appears to be overvalued given its negative valuation ratios, including a Price to Book Value of -0.04, an EV to EBIT of -0.66, and an EV to EBITDA of -0.67. Comparatively, peers such as Neurosense Therapeutics Ltd. have a significantly lower EV to EBITDA of -2.5448, indicating that Trevena's valuation metrics are not competitive within the industry. The stock has underperformed dramatically, with a year-to-date return of -83.33% compared to the S&P 500's positive return of 12.22%. Over the past year, Trevena's stock has declined by 94.38%, further emphasizing its overvaluation in the current market context....

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

5.71%

EBIT Growth (5y)

-4.55%

EBIT to Interest (avg)

-31.55

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.87

Sales to Capital Employed (avg)

0.05

Tax Ratio

0.24%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

15.89%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-0.04

EV to EBIT

-0.66

EV to EBITDA

-0.67

EV to Capital Employed

-6.86

EV to Sales

21.11

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

Bullish

Bollinger Bands

Sideways

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2024

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 5 Schemes (1.34%)

Foreign Institutions

Held by 6 Foreign Institutions (0.15%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'24 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2024 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2024 is 0.00% vs 36.36% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.30",
          "val2": "0.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.50",
          "val2": "-6.40",
          "chgp": "14.06%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.50",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.40",
          "val2": "1.80",
          "chgp": "-77.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.90",
          "val2": "-4.90",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-19,706.70%",
          "val2": "-20,009.20%",
          "chgp": "30.25%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is 875.00% vs -166.67% in Dec 2022",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is 24.95% vs -4.07% in Dec 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3.10",
          "val2": "-0.40",
          "chgp": "875.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-34.40",
          "val2": "-55.50",
          "chgp": "38.02%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.60",
          "val2": "1.30",
          "chgp": "176.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "2.10",
          "val2": "11.20",
          "chgp": "-81.25%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-40.30",
          "val2": "-53.70",
          "chgp": "24.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-11,292.20%",
          "val2": "0.00%",
          "chgp": "-1,129.22%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'24 - QoQ

Sep'24

Jun'24

Change(%)

Net Sales

0.30

Operating Profit (PBDIT) excl Other Income

-5.50

-6.40

14.06%

Interest

0.00

0.50

-100.00%

Exceptional Items

0.40

1.80

-77.78%

Consolidate Net Profit

-4.90

Operating Profit Margin (Excl OI)

-19,706.70%

-20,009.20%

30.25%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Sep 2024 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

QoQ Growth in quarter ended Sep 2024 is 0.00% vs 36.36% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'23

Dec'23

Dec'22

Change(%)

Net Sales

3.10

-0.40

875.00%

Operating Profit (PBDIT) excl Other Income

-34.40

-55.50

38.02%

Interest

3.60

1.30

176.92%

Exceptional Items

2.10

11.20

-81.25%

Consolidate Net Profit

-40.30

-53.70

24.95%

Operating Profit Margin (Excl OI)

-11,292.20%

0.00%

-1,129.22%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2023 is 875.00% vs -166.67% in Dec 2022

Consolidated Net Profit

YoY Growth in year ended Dec 2023 is 24.95% vs -4.07% in Dec 2022

All Annual Results

Company CV

About Trevena, Inc.

Trevena, Inc.

Pharmaceuticals & Biotechnology

Trevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers. It is also developing TRV250, a G protein biased ligand targeting the o-receptor, as a compound with a non-narcotic mechanism for the treatment of migraine. TRV250 also may have utility in a range of other central nervous system (CNS) indications. It is focused on commencing a Phase I study of TRV250 in the United Kingdom. Its ABLE product platform is a collection of biological information, in vitro assays, know-how and expertise that it uses to identify unique G protein coupled receptors (GPCR)-targeted biased ligands with various pharmaceutical properties.

Company Coordinates

Company Details

955 Chesterbrook Blvd Ste 110 , CHESTERBROOK PA : 19087-5627

Tel: 1 610 35488401 617 4307576

http://www.trevena.com/

Registrar Details

Trevena, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Trevena, Inc.?

Watch in Real-Time

What does Trevena, Inc. do?

Who are in the management team of Trevena, Inc.?

Is Trevena, Inc. overvalued or undervalued?

Is Trevena, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is Trevena, Inc. technically bullish or bearish?

Is Trevena, Inc. overvalued or undervalued?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2024

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'24 - QoQ

Annual Results Snapshot (Consolidated) - Dec'23

About Trevena, Inc.

Company Coordinates